These results showed the relevance of S100B as a maindriver of neuroinflammation in experimental autoimmune encephalomyelitis andidentified an uncharacterized mode of action of pentamidine, strengthening thepossibility to use this drug as an anti-inflammatory and remyelinating therapyfor progressive multiple sclerosis. This evidence concerns the gene S100B and experimental autoimmune encephalomyelitis.